CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin?

Nat Rev Cancer. 2007 Dec;7(12):925-36. doi: 10.1038/nrc2251.

Abstract

In the past decade, CHK2 has emerged as an important multifunctional player in the DNA-damage response signalling pathway. Parallel studies of the human CHEK2 gene have also highlighted its role as a candidate multiorgan tumour susceptibility gene rather than a highly penetrant predisposition gene for Li-Fraumeni syndrome. As discussed here, our current understanding of CHK2 function in tumour cells, in both a biological and genetic context, suggests that targeted modulation of the active kinase or exploitation of its loss in tumours could prove to be effective anti-cancer strategies.

Publication types

  • Review

MeSH terms

  • Aging / pathology
  • Aging / physiology
  • Antineoplastic Agents / therapeutic use
  • Apoptosis
  • Checkpoint Kinase 2
  • DNA Damage
  • Disease Susceptibility / enzymology
  • Humans
  • Mutation
  • Neoplasms / enzymology*
  • Neoplasms / genetics
  • Neoplasms / physiopathology
  • Neoplasms / therapy
  • Protein-Serine-Threonine Kinases / antagonists & inhibitors
  • Protein-Serine-Threonine Kinases / genetics
  • Protein-Serine-Threonine Kinases / metabolism*

Substances

  • Antineoplastic Agents
  • Checkpoint Kinase 2
  • CHEK2 protein, human
  • Protein-Serine-Threonine Kinases